Barbara Gayle Duncan Insider Trading Transactions

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Barbara Gayle Duncan.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Barbara Gayle Duncan. Barbara Gayle Duncan is Director in IMMUNOMEDICS INC ($IMMU) and Director in Innoviva, Inc. ($THRX) and CEO in Euthymics Bioscience Inc ($DOVP) and Director in Euthymics Bioscience Inc ($DOVP) and President and CFO in Euthymics Bioscience Inc ($DOVP) and Director in MEDGENICS, INC. ($MDGN) and Chief Accounting Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Chief Financial Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Director in Atea Pharmaceuticals, Inc. ($AVIR) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in Ovid Therapeutics Inc. ($OVID) and Director in Jounce Therapeutics, Inc. ($JNCE) and Director in Fusion Pharmaceuticals Inc. ($FUSN).

Latest Insider Trading Transactions of Barbara Gayle Duncan

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, ADAP, GNMX, AVIR, DOVP, FUSN, IMMU, THRX, ICPT, JNCE, OVID

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Nov 03 2020	FUSN	Fusion Pharmaceuti ...	Duncan Barbara Gayle	Director	Option Exercise	A	12.40	30,000	372,000	30,000
Oct 30 2020	AVIR	Atea Pharmaceutica ...	Duncan Barbara Gayle	Director	Option Exercise	A	24.00	80,000	1,920,000	80,000
Oct 30 2020	AVIR	Atea Pharmaceutica ...	Duncan Barbara Gayle	Director	Option Exercise	A	24.00	80,000	1,920,000	80,000
Oct 23 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	D	0.00	3,718	0	0
Oct 23 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	D	0.00	6,540	0	0
Oct 23 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Sell	D	0.00	49,244	0	0	49.2 K to 0 (-100.00 %)
Sep 16 2020	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	M	4.21	10,000	42,100	34,271
Sep 16 2020	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Sell	S	10.50	5,000	52,500	0	5 K to 0 (-100.00 %)
Sep 16 2020	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Sell	S	9.50	5,000	47,500	5,000	10 K to 5 K (-50.00 %)
Sep 16 2020	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Buy	M	4.21	10,000	42,100	10,000	0 to 10 K
Sep 15 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	M	16.96	2,500	42,400	0
Sep 15 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Buy	M	16.96	2,500	42,400	39,577	37.1 K to 39.6 K (+6.74 %)
Aug 20 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	M	16.96	20,000	339,200	0
Aug 20 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Buy	M	16.96	20,000	339,200	37,077	17.1 K to 37.1 K (+117.12 %)
Aug 14 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	M	12.93	17,077	220,806	0
Aug 14 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Buy	M	12.93	17,077	220,806	17,077	0 to 17.1 K
Jul 01 2020	ADAP	Adaptimmune Therap ...	Duncan Barbara Gayle	Director	Option Exercise	A	1.67	144,000	240,480	144,000
Jun 29 2020	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	A	7.58	13,550	102,709	13,550
Jun 22 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	A	33.62	6,540	219,875	6,540
Jun 22 2020	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Grant	A	0.00	3,718	0	13,385	9.7 K to 13.4 K (+38.46 %)
Jun 08 2020	OVID	Ovid Therapeutics ...	Duncan Barbara Gayle	Director	Option Exercise	A	5.29	13,250	70,093	13,250
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	D	2.84	10,591	30,078	0
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	D	8.09	40,000	323,600	0
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	D	4.83	20,000	96,600	0
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	D	1.32	20,000	26,400	0
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	D	1.55	50,000	77,500	0
Feb 05 2020	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Sell	D	0.00	59,524	0	0	59.5 K to 0 (-100.00 %)
Nov 15 2019	OVID	Ovid Therapeutics ...	Duncan Barbara Gayle	Director	Option Exercise	A	2.43	7,437	18,072	7,437
Jul 03 2019	ADAP	Adaptimmune Therap ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.61	124,000	75,640	124,000
Jun 13 2019	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	A	4.46	15,700	70,022	15,700
Jun 11 2019	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	A	12.93	17,077	220,806	17,077
Jun 11 2019	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Grant	A	0.00	9,667	0	9,667	0 to 9.7 K
Jun 10 2019	OVID	Ovid Therapeutics ...	Duncan Barbara Gayle	Director	Option Exercise	A	1.60	5,813	9,301	5,813
Mar 07 2019	IMMU	IMMUNOMEDICS INC	Duncan Barbara Gayle	Director	Option Exercise	A	16.96	22,500	381,600	22,500
Jun 26 2018	ADAP	Adaptimmune Therap ...	Duncan Barbara Gayle	Director	Option Exercise	A	2.18	158,233	344,948	158,233
Jun 21 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	A	7.92	13,550	107,316	13,550
Jun 18 2018	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	A	1.55	50,000	77,500	50,000
Jun 08 2018	OVID	Ovid Therapeutics ...	Duncan Barbara Gayle	Director	Option Exercise	A	8.12	5,813	47,202	5,813
Mar 19 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	M	4.21	2,000	8,420	44,271
Mar 19 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Sell	S	28.11	2,000	56,220	0	2 K to 0 (-100.00 %)
Mar 19 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Buy	M	4.21	2,000	8,420	2,000	0 to 2 K
Jan 29 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Option Exercise	M	4.21	4,000	16,840	46,271
Jan 29 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Sell	S	25.00	4,000	100,000	0	4 K to 0 (-100.00 %)
Jan 29 2018	JNCE	Jounce Therapeutic ...	Duncan Barbara Gayle	Director	Buy	M	4.21	4,000	16,840	4,000	0 to 4 K
Oct 18 2017	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	P	2.84	10,591	30,078	10,591
Oct 18 2017	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Buy	P	1.26	59,524	75,000	59,524	0 to 59.5 K
Aug 10 2017	GNMX	Aevi Genomic Medic ...	Duncan Barbara Gayle	Director	Option Exercise	A	1.32	20,000	26,400	20,000
Jul 03 2017	ADAP	Adaptimmune Therap ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.75	228,765	171,574	228,765
Jun 15 2017	OVID	Ovid Therapeutics ...	Duncan Barbara Gayle	Director	Option Exercise	A	13.91	11,627	161,732	11,627
Apr 24 2017	THRX	Innoviva, Inc.	Duncan Barbara Gayle	Director	Grant	A	0.00	19,857	0	52,318	32.5 K to 52.3 K (+61.17 %)
Nov 21 2016	THRX	Innoviva, Inc.	Duncan Barbara Gayle	Director	Grant	A	0.00	32,461	0	32,461	0 to 32.5 K
Oct 05 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Accounting Of ...	Sell	S	163.20	147	23,990	30,661	30.8 K to 30.7 K (-0.48 %)
Jul 07 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Accounting Of ...	Sell	S	145.11	146	21,186	30,808	31 K to 30.8 K (-0.47 %)
Apr 06 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	130.76	144	18,829	30,948	31.1 K to 30.9 K (-0.46 %)
Feb 12 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	A	95.74	8,100	775,494	8,100
Feb 12 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Grant	A	0.00	6,200	0	31,092	24.9 K to 31.1 K (+24.91 %)
Apr 19 2016	MDGN	MEDGENICS, INC.	Duncan Barbara Gayle	Director	Option Exercise	A	4.83	20,000	96,600	20,000
Jan 05 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	0.00	1,298	0	0
Jan 05 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	145.90	428	62,447	24,892	25.3 K to 24.9 K (-1.69 %)
Jan 05 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	145.90	40	5,836	25,320	25.4 K to 25.3 K (-0.16 %)
Jan 05 2016	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	0.00	1,298	0	25,360	24.1 K to 25.4 K (+5.39 %)
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	0.00	1,298	0	1,298
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	8.67	1,000	8,667	6,940
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	A	161.16	10,600	1,708,296	10,600
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	159.04	54	8,588	24,062	24.1 K to 24.1 K (-0.22 %)
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	163.39	1,000	163,390	24,116	25.1 K to 24.1 K (-3.98 %)
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	0.00	1,298	0	25,116	23.8 K to 25.1 K (+5.45 %)
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	8.67	1,000	8,667	23,818	22.8 K to 23.8 K (+4.38 %)
Oct 05 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Grant	A	0.00	4,050	0	22,818	18.8 K to 22.8 K (+21.58 %)
Jul 23 2015	MDGN	MEDGENICS, INC.	Duncan Barbara Gayle	Director	Option Exercise	A	8.09	20,000	161,800	20,000
Jul 07 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	0.00	1,298	0	2,596
Jul 07 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	239.00	1	239	18,768	18.8 K to 18.8 K (-0.01 %)
Jul 07 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	238.16	2	476	18,769	18.8 K to 18.8 K (-0.01 %)
Jul 07 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	236.13	50	11,807	18,771	18.8 K to 18.8 K (-0.27 %)
Jul 07 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	0.00	1,298	0	18,821	17.5 K to 18.8 K (+7.41 %)
Jul 06 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	8.67	1,000	8,667	7,940
Jul 06 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	242.10	1,000	242,100	17,523	18.5 K to 17.5 K (-5.40 %)
Jul 06 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	8.67	1,000	8,667	18,523	17.5 K to 18.5 K (+5.71 %)
Apr 03 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Option Exercise	M	0.00	1,298	0	3,894
Apr 03 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	277.70	39	10,830	17,523	17.6 K to 17.5 K (-0.22 %)
Apr 03 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Buy	M	0.00	1,298	0	17,562	16.3 K to 17.6 K (+7.98 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	293.34	300	88,001	16,264	16.6 K to 16.3 K (-1.81 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	292.16	100	29,216	16,564	16.7 K to 16.6 K (-0.60 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	291.00	100	29,100	16,664	16.8 K to 16.7 K (-0.60 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	289.00	100	28,900	16,764	16.9 K to 16.8 K (-0.59 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	288.00	100	28,800	16,864	17 K to 16.9 K (-0.59 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	287.00	100	28,700	16,964	17.1 K to 17 K (-0.59 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	286.00	100	28,600	17,064	17.2 K to 17.1 K (-0.58 %)
Apr 01 2015	ICPT	INTERCEPT PHARMACE ...	Duncan Barbara Gayle	Chief Financial Off ...	Sell	S	285.00	100	28,500	17,164	17.3 K to 17.2 K (-0.58 %)
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	550,000	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	550,000	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	550,000	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	698,500	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	724,500	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	A	0.00	705,500	0	3,778,500
May 20 2008	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	Director	Option Exercise	D	0.00	5,830,709	0	3,778,500
Aug 13 2007	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	CEO	Option Exercise	A	0.33	5,031,209	1,660,299	5,830,709
Jan 23 2007	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	President and CFO	Option Exercise	A	0.39	75,000	29,250	799,500
Jul 05 2006	DOVP	Euthymics Bioscien ...	Duncan Barbara Gayle	President and CFO	Option Exercise	A	2.12	350,000	742,000	724,500

Page: 1